Vericiguat yog ibpyrazolopyridineuas yog5-fluoro-1H-pyrazolo[3,4-b]pyridinenyob rau hauv uas cov amino hydrogen ntawm txoj hauj lwm 1 tau hloov los ntawm ib pawg 2-fluorobenzyl thiab covhydrogenntawm txoj hauj lwm 3 tau raug hloov los ntawm 4,6-diamino-5-[(methoxycarbonyl)amino] pyrimidin-2-yl pawg. Nws yog solubleguanylatecyclase stimulator uas yog siv rau kev kho mob plawv tsis ua hauj lwm. Nws muaj lub luag hauj lwm raws li ib tug solubleguanylatecyclase activator, tus neeg sawv cev vasodilator thiab cov tshuaj tiv thaiv kab mob. Nws yog ibaminopyrimidine, apyrazolopyridine, carbamate ester thiab organofluorine compound.

Vericiguat tab tom tshawb nrhiav hauv kev sim tshuaj NCT02861534 (A Study of Vericiguat in Participants With Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-001)).

Vericiguat yog SolubleGuanylateCyclase Stimulator. Lub mechanism ntawm kev txiav txim ntawm vericiguat yog raws li ib tugGuanylateCyclase Stimulator.

Vericiguat yog cov tshuaj siv los tswj thiab kho lub plawv tsis ua hauj lwm nrog txo ejection feem (HFrEF). Nws yog pab tau rau mob plawv tsis ua hauj lwm, tsis ntev los no decompensated plawv tsis ua hauj lwm. Vericiguat tsis ua kom muaj sia nyob ntev tab sis tiv thaiv kev kho mob. Qhov kev ua no qhia txog cov kev qhia, cov txheej txheem ntawm kev ua, koob tshuaj, thiab hom kev tswj hwm los ntawm pab pawg neeg sib koom tes, cov teebmeem tsis zoo, contraindications, thiab ntau qhov kev sim los txhawb cov pov thawj ntawm cov tshuaj muaj txiaj ntsig hauv HFrEF.